The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Are Insurance Companies’ Medication Directives Fiscally, Medically Questionable?

Are Insurance Companies’ Medication Directives Fiscally, Medically Questionable?

November 1, 2014 • By Bruce Rothschild, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Insurance Company Medication Directives

Fiscally, as well as medically ‘questionable’?

You Might Also Like
  • Opinion: Insurance Companies Use Medically and Fiscally Irresponsible Formularies
  • PRACTICE PAGE: The ACR Takes on Insurance Companies
  • The Battle with Insurance Companies to Obtain Prescriptions
Explore This Issue
November 2014
Also By This Author
  • Opinion: Insurance Companies Use Medically and Fiscally Irresponsible Formularies

Insurance companies have traditionally denied the accusation that their “behavior” represents the practice of medicine without a license, claiming they don’t prohibit care. Rather, they have claimed to be indicating the limits of their coverage. It is unclear if their medical directors are participants in the formulary process or simply figureheads. Now, insurers seem to deviate from that approach, actually promoting their preferred practices and medications directly to patients, independent of the safety or efficacy of those practices. In doing so, have they undermined and compromised the ability of practicing physicians to provide quality care? Such behavior includes contacting patients directly and instructing pharmacies to push medications they knew or should have known did not meet equivalency requirements or were documented as not equivalent and less safe.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Unnecessary gastrointestinal bleeds related to lack of effective gastroprotection clearly exemplify this issue. The MUCOSA study clearly documented twofold reduction of gastrointestinal events requiring hospitalization for individuals age 52 and older, contrasted with rules limiting access to those who have achieved age 65.1,2

Prior requirement (for use of a COX-2 agent) for evidence of misadventure with or therapeutic response failure of two less safe (2% hospitalizations for gastrointestinal events per year) agents does not seem medically justifiable or fiscally responsible.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Promoting and substitution of components for a combination medication (e.g., Arthrotec), if they were clinically equivalent, might be acceptable—if the appropriate time course was observed. It’s not. The misoprostol component must be taken 20 minutes prior to the diclofenac component if gastroprotection is to be achieved. However, there is another problem. There are multiple classes of bioequivalence, not all of which actually require documentation of that bioequivalence. Further, there is a difference between chemical and clinical equivalence. Misoprostol, formulated as a component of Arthrotec, even given once per day, has been documented to reduce major gastrointestinal complications by 50%.1,2 Separate administration of diclofenac and misoprostol at equivalent dose lacks that efficacy! Achieving a similar safety profile requires the misoprostol be taken at least three and, preferably, four times per day.3

Similarly, care is compromised by promoting use of alendronate (Fosamax), despite documentation that one in eight women with arthritis experience a 2 gram hemoglobin drop within three months of starting that medication, a complication not found with alternatives for treatment of osteoporosis.4 This appears not only medically irresponsible, but also does not appear to be cost effective from a fiscal perspective.

Pages: 1 2 | Single Page

Filed Under: Drug Updates, Legal, Practice Management, Professional Topics, Quality Assurance/Improvement, Safety Tagged With: drug, insurance, Medicare, patient care, pharmaceutical, Rothschild, SafetyIssue: November 2014

You Might Also Like:
  • Opinion: Insurance Companies Use Medically and Fiscally Irresponsible Formularies
  • PRACTICE PAGE: The ACR Takes on Insurance Companies
  • The Battle with Insurance Companies to Obtain Prescriptions
  • Commentary: Generic Drugs Can Increase Opportunities for Medication Errors

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.